Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel vs Paclitaxel + Carboplatin in Advanced NSCLC
NCT00003117Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 1997
- Primary completion
- Dec 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival at 2 years. Started Oct 1997; status: completed.
02
Drugs
carboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00003117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003117.